Overview

Pharmacokinetics, Safety and Tolerability Study of Single Dose of Abatacept 125mg Administered Subcutaneously

Status:
Unknown status
Trial end date:
2017-02-01
Target enrollment:
Participant gender:
Summary
The objective of the study is to assess the single dose PK, safety, tolerability and immunogenicity of abatacept 125mg administered SC in Chinese healthy subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Jiangsu Simcere Pharmaceutical Co., Ltd.
Collaborator:
Bristol-Myers Squibb
Treatments:
Abatacept